SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: H. Bradley Toland, Jr. who wrote (83)9/21/1998 4:56:00 PM
From: Biomaven  Read Replies (1) of 127
 
I've been told by a nephrologist that the pre-dialysis market is, in the long run, more significant for Renagel than the dialysis market, and that informed nephrologists will start using it for these patients as soon as it is approved.

One question I have is whether NPSP/Amgen's calcimimetic (currently in Phase II) will be competition down the road, if and when it is approved.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News